Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 52-week, randomised, double-blind, parallel-group, multi-centre, phase IIIB study comparing the long term safety of SYMBICORTO pMDI 160/4.5 mg x 2 actuations twice daily to budesonide HFA pMDI 160 mg x 2 actuations twice daily in adult/adolescent (greater than or equal to12 years) African American subjects with asthma.

Next Previous
Trial Profile

A 52-week, randomised, double-blind, parallel-group, multi-centre, phase IIIB study comparing the long term safety of SYMBICORTO pMDI 160/4.5 mg x 2 actuations twice daily to budesonide HFA pMDI 160 mg x 2 actuations twice daily in adult/adolescent (greater than or equal to12 years) African American subjects with asthma.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 09 Feb 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Budesonide/formoterol (Primary) ; Budesonide
  • Indications Asthma
  • Focus Adverse reactions
  • Sponsors AstraZeneca

    • Most Recent Events

    • 10 May 2012 Results from this trial published in the Journal of Allergy & Clinical Immunology in May 2012, according to an AstraZeneca media release. Top-line tolerability results were reported also in the media release.
    • 06 Mar 2012 Long-term cardiovascular safety results presented at the 68th Annual Meeting of the American Academy of Allergy, Asthma and Immunology.
    • 27 Oct 2011 Results presented at the 77th Annual Meeting of the American College of Chest Physicians: Chest 2011.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top